actin related protein 2/3 complex subunit 5 likeGenealiases: ARC16-2 · ARPC5B
Q-omics provides the consensus-scored ARPC5L profile across patient tissues and cancer cell-line models. ARPC5L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ARPC5L is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ARPC5L protein abundance shows 35,748 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, COAD, and PDAC as cancer lineages where ARPC5L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARPC5L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARPC5L survival associations across molecular data types. ARPC5L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARPC5L RNA expression–survival associations across cancer types. High ARPC5L expression shows unfavorable associations in ACC, COAD, LIHC, UCS, BRCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ARPC5L RNA expression.
This table summarizes ARPC5L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARPC5L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARPC5L shows higher tumor expression in COAD, LIHC, LUAD, LUSC, HNSC and STAD. The COAD box plot shows higher ARPC5L RNA expression in tumor versus normal tissue (log2 FC = +0.815, t-test p < 0.001).
This table shows molecular features associated with ARPC5L in patient tissues and cancer cell lines. In patient samples, ARPC5L shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARPC5L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BONE.
